The trusted partner. For better lives.
Who we are
We develop and manufacture medicines, ensuring a safe supply of life-improving products. This is done by our 200 proficient employees at our four sites in Norway. Curida is on a growth journey where revenue and growth is expected to continue in the coming years, as a series of products is currently being added to the Curida portfolio through technology transfer and product development projects.
In Curida, we live by our core values. We are:
1. Introduction
Corporate ethics are about how we behave towards each other and the world around us. The Code of Conduct (CoC) is the foundation of our corporate culture and defines the core principles and ethical standards by which we create value in our company. The CoC gives guidelines to how we shall behave both internally and externally. CoC shall stimulate ethical awareness and be a guideline for everyday actions.
The CoC applies to all member of the board, all employees and representatives of Curida. Curida aims for these guidelines also to be well known by customers, suppliers, acquired companies and partners. All managers are responsible for the CoC being known, lived up to, and that actions will be taken if codes are broken. Each employee has a responsibility to read and follow the CoC.
Violation of the CoC will be subjected to disciplinary action including possible termination as well as potential criminal prosecution. To ensure that every part of our value chain fulfils Curida’s high standards of quality and ethical conduct, we routinely perform controls on compliance with the principles described in this document.
2. Values, personal conduct, working environment and human rights
In Curida, we live by our core values. These values guide our behaviour and our decisions – internally and externally.
Curida expects employees who live by our values, who treat others with respect and maintain an open communication. In Curida there shall be no discrimination or harassment of age, gender, disabilities, race, sexual orientation, ethnic origin, religion or political affiliation. Curida shall be an engaging workplace with an inclusive working environment. Curida expects that no employees make any actions that could harm the Curida brand.
When we are working in other cultures than our own, we treat everyone – persons as well as organisations – with respect, and we are acting in accordance with national laws and regulations. We also pay attention to local etiquette and values in the countries we are working in. In meetings with contacts outside Curida we appear as professionals in behaviour and conduct. Curida supports and respects internationally proclaimed human rights, including those specified by the International Labour Organization. The company respects the right to freedom of association and opposes any form of child labour, forced labour or discrimination, and requests all representatives and suppliers to follow the same principles.
Curida undertakes development services and manufacturing of pharmaceutical products. We therefore operate in a highly regulated business, where premium quality on products and processes are of the highest importance.
3. Sustainability
We manage our environmental impact and seek to continuously improve the sustainability of our activities by. We work to increase efficiency of the use of renewable energy in our facility, economizing on our use of non-renewable energy and raw materials; minimizing the amount of waste we generate, and minimizing any adverse environmental effects associated with the manufacturing of products in our portfolio.
Curida strictly complies with all environmental, health, and safety laws that apply to our operations, but we also strive to go beyond legal minimums to proactively reduce the potential for environmental impact of our activities. We aim to work with partners who also regard minimal environmental impact of their value chain as an increased quality in the end product, namely a safe and effective pharmaceutical product or medical device.
4. Conflicts of interests
No personal interests or personal gain shall affect your work in Curida. As an employee you shall never take actions or have interests that make it difficult to perform your work objectively and effectively. You shall never be a part of, or influence decisions or actions, where you can be a part of a conflict of interest between you and the company. In such situations Curida is expecting openness and loyalty to Curida.
Curida employees shall not hold positions or carry out work for other companies without permission from a superior. Engagements in external duties and positions shall not affect your working relationship with Curida. Each employee is responsible to inform Curida management about a real or potential conflict of interest.
Curida was established when a group of employees and management acquired the Takeda manufacturing site in Elverum, Norway in 2015. The acquisition followed Takeda’s decision to shut the site down and move all manufacturing to other parts of Europe. The manufacturing site, which has existed since 1974, had been part of Nycomed until 2011.
Under Takeda, the Elverum site had around 200 employees and was the largest private employer of the area. Curida started out with a smaller operation at its inception in 2015. Since then, the site has experienced significant growth in terms of both revenue and employment, and it will in the near future approach the size it saw at its historic peak in 2013.
The employees showed great courage when starting their own company under uncertain conditions in 2014 and 2015. Before Norwegian Prime Minister Erna Solberg reopened the Elverum site under the Curida name on July 1st 2015, the employees had put more than 10,000 hours of volunteer work into making the new company a reality.
The employees and management remained the only owners of Curida until December 2017, when Norwegian family offices Canica and Klaveness Marine invested in Curida. Shortly after, the Norwegian governmental investment fund Investinor and family office Stokke Industri followed. The employees and management still control more than 20 percent of the shares in Curida.
In 2018, to increase the Norwegian footprint, Curida acquired Ås Produksjonslab, located south of Oslo. Ås Produksjonslab performs fill and finish of bottle products for the Norwegian pharmacy market.
The growth continues, and in 2022 Curida acquired Diatec Monoclonals, a biologics company in Oslo. With this Curida is entering the biologics market and is as such positionned for further growth.
Anders has been acting COO at Curida since fall 2023 and became CEO in May 2024. He brings extensive experience from the pharma, pharmacy and pharma services industry from his role as CEO in Norway for Boots pharmacy and Alliance Healthcare pharma wholesale (Cencora). Furthermore, Anders has over a decade of experience in development and end-to-end operations in FMCG, food and beverage from multiple executive roles in Orkla and Carlsberg, located in Scandinavia and in Asia. Anders holds an MSc in Chemical Engineering from Chalmers University Gothenburg and Imperial College London, as well as a BSc in finance from Gothenburg University.
Álvaro López joined Curida as Business Development Director in January 2025. In this role, Álvaro will be fully responsible for overseeing Commercial Operations, including Sales, Marketing, and Business Intelligence. With over 20 years of experience in Business Development and Sales within the Healthcare and Pharmaceutical industries, Álvaro brings a wealth of expertise in sterile liquid technologies, particularly in BFS technologies and Nasal Sprays. He has previously held several senior commercial positions, including Sales & Marketing Director and Business Development Director, within the CDMO sector. Álvaro holds a degree in Law, a Postgraduate degree in International Business, and an Executive MBA from IE Business School.
Terje Gabrielsen has been Chief Financial Officer of Curida since September 2017. Prior to his appointment in Curida, he worked as CFO Thales Norway, Denofa, Nammo Group, Raufoss Group, Unitor North America and Alcatel Telettra. Mr Gabrielsen holds an MSc in Business Administration from BI Norwegian Business School.
Jens Schanche Dølør possesses a comprehensive background in military education and experience, having held various leadership and human resources roles across different levels within the armed forces. Additionally, he has garnered HR expertise from the healthcare sector. Since March 2024, Jens has served as the Head of Human Resources at Curida Group. In this capacity, he and his HR team deliver a full spectrum of HR support to all organizational levels.
Joe joined Curida in November 2024. Having worked within the pharma industry since 1999, Joe has gained significant international experience leading operations with complex product portfolios for both big pharma and CDMO. Joe has a proven background in building sustainable operational capability and operational excellence within small molecule API’s, finished goods and medical devices.
Joe holds an MSc in Manufacturing from the OU, and a BSc in Engineering Systems from Napier university, Edinburgh.
Peter Sjølie holds a M.Sc. in Production Technology from NTNU Trondheim. Since graduating Peter has worked in the Norwegian research organization SINTEF and space and defence group NAMMO. Starting as a project manager responsible for tech transfers (TT) in Curida in 2019 Peter has obtained extensive experience in the pharmaceutical industry. Especially through leading Curida’s single largest TT-project transferring 15 products (200+ SKU’s) over the course of two years. Since Q4 2021 Peter has been responsible for all tech transfer and development projects in Curida Small Molecules.
Ørjan Leiknes Apeland holds an MScPharm degree from the University of Oslo, obtained in 2016. Since graduating, he has accumulated extensive experience in the pharmaceutical industry, focusing on quality control and manufacturing. Mr. Apeland commenced his role with the Curida Group in 2020 and currently holds overall responsibility for Ås Produksjonslab AS. He also has the overall responsibility for sustainability in the group.
Mira has an M.Sc in Molecular Bioscience and Immunology and joined Curida in 2018. She spent her first 3 years as Key Account Manager before moving on to the role of Site Manager at our Diagnostics production site. When the company was acquired by Curida AS in 2022, Curida Diatec reorganized and Mira was asked to temporary lead operations at the two manufacturing sites in addition to business development. In May 2024 Mira was promoted to Director of Curida Biologics. Mira has a background from Basal Medical Research at Oslo University Hospital and a broad experience in sales and customer service from other industries.
Nikhil Puri has had an almost 30-year association with the pharmaceutical industry, in the capacity of an investor, senior executive and investment banker. He is currently a Partner at Signet Healthcare Partners that invests extensively in the pharma and pharma services sectors and manages the firms’ investments in Curida, Laxai Life Sciences, Leading Pharma, and GBI Biomanufacturing. Previously he led global business development for the Established Pharma business within Pfizer that generated approximately $25 billion in annual revenues across five continents. Before Pfizer, he spent 15 years on Wall Street as a senior investment banker covering the pharma sector and was involved in M&A and capital markets transactions that exceeded $40 billion in value.
Ole has over 25 years of experience in the life sciences industry, including co-founding three start-ups and holding leadership roles at Qiagen, Life Technologies, and Thermo Fisher Scientific. As VP & General Manager of Thermo Fisher’s Cell Biology Division, he led global operations until 2021. Dahlberg now serves as an independent executive and board member for biotech companies. He holds a Master of Science in Genetics and Marine Biology from the University of Oslo and has a proven track record in driving innovation, business growth, and R&D in the life sciences sector.
Jonathan is a seasoned leader with 30 years in the CDMO industry, specializing in transformational change, leadership development, and sustainable growth. He spent 12 years at Catalent Pharma Solutions, serving as Divisional President and Chief Commercial Officer. Before that, he held senior roles at Patheon (Thermo Fisher), including VP Global Supply Chain and Chief Procurement Officer. With deep industry connections across the Pharma and Biotech industry he has international experience across the UK, Italy, Switzerland, and the US. He serves on the boards of Advancion Sciences, Aktiv Medical Systems, and Curida AS and advises the industry through his company Bluefin Pharma Consulting GmbH.
Patrick, Investment Director at Investinor, joined Curida’s board in 2024. He has served on multiple boards including Cyviz, Ovun, Sensibel, Topro Mobility, and Zilift since 2017. He actively engages with portfolio companies Dignio and Spinchip and Investinor’s listed firms, specializing in health and deep tech sectors. With a background in investment banking at Pareto and auditing at Deloitte, he brings expertise in finance, manufacturing, strategy, governance, and transactions to Curida.
Tone has over 30 years of experience in quality management, including 20+ years in pharmaceutical and medical device manufacturing. She spent 13 years at Nycomed/Takeda as Head of Quality & Technology, leading audits and inspections, followed by 7+ years in Takeda’s Global Quality Auditing function. Now a Quality Specialist at Curida, she has expertise in tech transfer (QA & Regulatory CMC) and medical device regulations (QMS, MDD/MDR). She holds an MSc in Organic Chemistry from the Technical University of Trondheim (NTNU).
Aina is an elected board member with over seven years of experience in the life sciences industry. She has a strong background in R&D project management and process optimization. Aina spent five years at SERO as a Product Formulation Expert and R&D Project Manager, gaining significant expertise in scaling up manufacturing practices and implementing new processes. In 2023, she transitioned to Curida Diatec as an R&D Scientist, where she now serves as a subject matter expert in downstream processes with expertise in production technology. Aina’s key strengths include process qualification, optimizing manufacturing workflows, and driving innovation in product development. Aina holds a Master of Science in Biology from the University of Copenhagen, bringing strong academic grounding to her industry experience.
Contact
Want to partner with us?
Contact us to learn more about our pharmaceutical development or manufacturing solutions. We look forward to discussing your next project with you! Our customers range from academic research, start-ups and early stage Biotech companies, to Big Pharma.
Curida Diatec
Martin Linges vei 25
1364 Fornebu
Norway
Director, Ås produksjonslab
Ørjan L. Apeland
orjan.apeland@aasproduksjonslab.no
Customer service, raw materials
Mette Stenstad
mette.stenstad@curida.no
Ås Produksjonslab
Gamleveien 2
1434 Ås
Norway
post@aasproduksjonslab.no
This website uses cookies